Delivery Order SPE2DB22D1106-SPE2DB25FFDQ3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $1,092.72 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 9, 2025. This non-competitive delivery order was issued on September 8, 2025, and represents a firm fixed-price pharmaceutical supply transaction. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company serves as a primary pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,537.84 firm fixed price delivery order on July 29, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 30, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and running through December 2026. The product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order valued at $1,405.80 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded transaction. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of August 26, 2025. This order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $3,132.65. This is a firm fixed-price delivery order with an ultimate completion date of August 1, 2025, and represents a non-competitive set-aside award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $2,001.20 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Novolog 100 Unit/mL FlexPen 3mL insulin pens. This contract utilizes firm fixed price terms with an ultimate completion date of August 6, 2025, and carries no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $1,553.22 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This non-competitive delivery order was issued on May 30, 2025, with an ultimate completion date of June 2, 2025, and reflects a firm fixed-price contract structure. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and...
- The Defense Logistics Agency awarded a $3,834.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of August 18, 2025. This non-set-aside contract was competitively awarded on August 15, 2025, with performance occurring at the vendor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship...
- The Defense Logistics Agency awarded a $4,479.33 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of August 20, 2025. This non-set-aside contract was competitively awarded and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government....
- The Defense Logistics Agency awarded a $3,064.44 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, which represents a non-competitive delivery order, will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 10, 2025. This award falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFDQ3Delivery Order
The Defense Logistics Agency awarded a $2,661.40 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This contract represents a competitive, non-set-aside award under a firm fixed-price arrangement with an ultimate completion date of August 18, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military and veteran healthcare systems. This specific delivery order for insulin pens supports the company's ongoing role as a primary pharmaceutical vendor for federal health programs, including the Defense Health Agency and U.S. Coast Guard, ensuring the availability of essential medications across the Department of Defense medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 8/15/25 |